Raymond James Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a $85 PT

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 17, Christopher Raymond from Raymond James maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and set a price target of $85.00.

BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds is Buying

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported total revenues of $825 million in fiscal Q2 2025, up 16% year-over-year and up 17% year-over-year at constant currency. GAAP diluted earnings per share (EPS) for the quarter reached $1.23.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.